The institute backed the treatment after seeing that biliary tract cancer patients on Ziihera lived for an average 18 months, much longer than those on standard chemo can expect.

While the safety was more manageable, questions remain about whether the combination would best antibody-drug conjugate ...

Lilly will pay $3.25 billion upfront with possible additional payments linked to the achievement of clinical, regulatory, and commercial milestones.

The platform trial will add new arms testing Enhertu in solid tumors with HER2 amplification and gather data on Tafinlar-Mekinist's tissue-agnostic benefit for regular approval.

The firm will begin enrolling patients into the pivotal Part C cohort of its Phase I/II/III LIGHTHOUSE trial of ATSN-201 later this month.

The firm will use the funds to advance its KIR-CAR platform, which adapts dual receptors from NK cells to allow CAR T cells to rest when not actively targeting tumors.

The firm will launch a new pivotal trial after the EMA's CHMP last year recommended against conditional marketing authorization for the gene therapy.

The firm also said this week that the NCCN added the HER2xHER3 bispecific antibody to its biliary tract cancer treatment guidelines.

While bota-vec failed to meet a Phase III primary endpoint, MeiraGTx remains committed to bringing the gene therapy to patients with X-linked retinitis pigmentosa.

NEW YORK – PrecisionLife and Ovation.io on Wednesday said they inked an agreement to launch a consumer-facing genetic test for identifying patients' likelihood of responding to GLP-1 receptor agonists ...

In the ARROW trial, researchers found that different RET fusion partners affected the durability of patients' responses, a finding that could be useful for guiding treatment.